share_log

Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $4

Benzinga ·  Nov 8 20:27  · Ratings

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:CHRS) with a Outperform and lowers the price target from $8 to $4.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment